Effect of DLBS1033 After Primary PCI in Patients With STE-ACS
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, double-dummy, and controlled clinical study
over a total of 4-week therapy with DLBS1033 in the management of STE-ACS after a primary
PCI. There will be 40 STE-ACS subjects (20 subjects in each group) planned to complete the
study.